ARTICLE | Company News
Aviragen, HealthCare Royalty Partners deal
May 2, 2016 7:00 AM UTC
Aviragen sold an undisclosed portion of its Inavir laninamivir octanoate royalty rights to HealthCare Royalty Partners for $20 million. Aviragen said it receives about $4.5 million annually from Inav...